NEW STUDY BY BIOTRENDS HIGHLIGHTS THE RISK TO TNF-ALPHA INHIBITORS OF LOSING PATIENT SHARE TO ALTERNATIVE MECHANISM AGENTS IN THE TREATMENT OF RHEUMATOID ARTHRITIS

THE PHOSPHATE BINDER MARKET IS CURRENTLY STABLE DESPITE TALKS OF MAJOR CHANGES IN JANUARY 2011 ONCE THE DIALYSIS BUNDLED PAYMENT SYSTEM TAKES EFFECT

CHANGES BREWING IN THE RENAL ANEMIA MARKET, ACCORDING TO TWO RECENT PUBLICATIONS FROM BIOTRENDS

NEUROLOGISTS EAGERLY AWAIT NEW ORAL TREATMENT OPTIONS FOR MULTIPLE SCLEROSIS SUCH AS EMD SERONO’S MOVECTRO AND NOVARTIS’S GILENIA